Merck & Company Inc (MRK)vsEverpure, Inc. (P)
MRK
Merck & Company Inc
$113.11
+0.04%
HEALTHCARE · Cap: $277.02B
P
Everpure, Inc.
$74.63
+2.58%
TECHNOLOGY · Cap: $23.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1696% more annual revenue ($65.77B vs $3.66B). MRK leads profitability with a 13.6% profit margin vs 5.1%. P appears more attractively valued with a PEG of 1.61. P earns a higher WallStSmart Score of 55/100 (C-).
MRK
Buy53
out of 100
Grade: C-
P
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.8%
Fair Value
$97.68
Current Price
$113.11
$15.43 premium
Intrinsic value data unavailable for P.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 1.8B in free cash flow
Earnings expanding 139.7% YoY
Revenue surging 20.4% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Trading at 17.0x book value
5.1% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bull Case : P
The strongest argument for P centers on EPS Growth, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : P
The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 130.2x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while P is a growth play — different risk/reward profiles.
P carries more volatility with a beta of 1.44 — expect wider price swings.
P is growing revenue faster at 20.4% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
P scores higher overall (55/100 vs 53/100) and 20.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Everpure, Inc.
TECHNOLOGY · COMPUTER HARDWARE · USA
Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?